Kelly Paul Edward's Form 4 filing
Relmada Therapeutics, Inc. (RLMD) · filed Nov 6, 2025
- Accession no.
- 0001213900-25-106835
- Filed
- Nov 6, 2025
- Trade date
- Nov 5, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $198.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kelly Paul EdwardCIK 0001658544 | Director, Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 5, 2025 | Common Stock | PPurchaseAcquired | +90,000 | $2.20 | +$198,000 | 502,295 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.